Figure 2
Figure 2. EBV lytic cycle progression enhances IL-13 expression. EBV negative (−) or EBV positive (+) Akata B-cell lines were treated with or without 10 μg/mL goat anti–human IgG antibody (α-hIgG Ab). RNA, supernatants, and cell lysates were harvested after 48 hours. Expression of IL-13 transcripts and protein was measured by RT-Q-PCR (A) and ELISA (B). The relative expression levels of IL-13 transcripts were normalized by the amount of IL-13 expressed in EBV(−) Akata B cells. (C) Expression of EBV latent (EBNA1) or lytic (Zta and Rta) proteins was detected by Western blot analysis; β-actin served as the internal control.

EBV lytic cycle progression enhances IL-13 expression. EBV negative (−) or EBV positive (+) Akata B-cell lines were treated with or without 10 μg/mL goat anti–human IgG antibody (α-hIgG Ab). RNA, supernatants, and cell lysates were harvested after 48 hours. Expression of IL-13 transcripts and protein was measured by RT-Q-PCR (A) and ELISA (B). The relative expression levels of IL-13 transcripts were normalized by the amount of IL-13 expressed in EBV(−) Akata B cells. (C) Expression of EBV latent (EBNA1) or lytic (Zta and Rta) proteins was detected by Western blot analysis; β-actin served as the internal control.

Close Modal

or Create an Account

Close Modal
Close Modal